## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.7% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($775.16)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. McKesson Corporation $MCK Shares Sold by Lombard Odier Asset Management USA Corp**
- Source: MarketBeat | 20251209T133143 | Neutral | Relevance: 99%
-  Lombard Odier Asset Management USA Corp significantly reduced its stake in McKesson Corporation (NYSE:MCK) by 57.8% in the second quarter, selling over 4,200 shares. Despite this, several other institutional investors, including Norges Bank and Nuveen LLC, purchased new stakes or increased their holdings in McKesson during recent quarters. Analysts hold a "Moderate Buy" rating for McKesson with a consensus target price of $892.86.

**2. Quantbot Technologies LP Has $1.40 Million Holdings in McKesson Corporation $MCK**
- Source: MarketBeat | 20251208T110544 | Bullish | Relevance: 98%
-  Quantbot Technologies LP significantly reduced its stake in McKesson Corporation, selling 65.2% of its shares but still holding 1,906 shares valued at approximately $1.40 million. McKesson has largely positive Wall Street sentiment with a "Moderate Buy" rating and an average price target of $887.69, following an EPS beat and a 10.2% revenue increase year-over-year. The company recently announced a quarterly dividend of $0.82 per share.

**3. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna Invests $1.87 Million in McKesson Corporation $MCK**
- Source: MarketBeat | 20251209T134343 | Bullish | Relevance: 98%
-  Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna recently acquired a new stake of 2,552 shares, valued at approximately $1.87 million, in McKesson Corporation (NYSE:MCK). This investment is part of a broader trend where institutional investors and hedge funds own 85.07% of McKesson's stock, alongside recent adjustments in holdings by other investment firms. McKesson has also received favorable analyst ratings and recently announced a quarterly dividend, indicating ongoing investor confidence and strong financial performance.

**4. 1 Healthcare Stock with Impressive Fundamentals and 2 We Brush Off**
- Source: Markets Financial Content | 20251208T040915 | Bullish | Relevance: 94%
-  This article evaluates three healthcare stocks, recommending McKesson (MCK) due to its strong financials, market scale, and effective share repurchases. Conversely, Omnicell (OMCL) and Labcorp (LH) are identified as less attractive investments due to stagnant sales, declining margins, and increased costs. The analysis provides fundamental reasons for investors to consider buying McKesson while being cautious about Omnicell and Labcorp.

**5. Precision Medicine Software Market to Hit USD 5.25 Billion**
- Source: openPR.com | 20251209T065408 | Somewhat-Bullish | Relevance: 62%
-  The global Precision Medicine Software Market is projected to reach US$ 5.25 billion by 2033, growing at a CAGR of 12.1% from US$ 1.89 billion in 2024. This growth is driven by the increasing demand for personalized healthcare solutions and advancements in genomic sequencing and big data analytics. North America currently leads the market, while Asia-Pacific is rapidly emerging as a high-growth region.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $101.1B |
| Beta | 0.38 |
| 52W Range | $558.13 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.6 |
| Current P/E | 21.0 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -6.6% to -2.7% (+3.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.7pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-9.62), momentum weakening. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.68% (CS: 20) | Weak |
| RSI_14 | 44.7 | Neutral |
| MACD Histogram | -9.62 | Bearish |
| vs SMA20 | 0.965x | Below |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 1.120x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $813.10
- **Stop Loss:** $775.16 (4.7% risk)
- **Target:** $851.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 13
- **Position Value:** $10,570.30
- **Portfolio %:** 10.57%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*